101 completed, 53 recruiting, 46 active not recruiting, 43 terminated. 158 Phase 2, 120 Phase 1, 52 Phase 3, 7 Not applicable, 3 Phase 4.
Follow pomalidomide: new trials by email Literature Review of pomalidomide trials Research Report on pomalidomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-11-04 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | 108 | 2026-12-01 | 2026-09-21 |
| Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma CM336, CM313, Daratumumab - Multiple Myeloma (MM) | Phase 3 | Not yet recruiting | Keymed Biosciences Co.Ltd | 320 | 2026-12-01 | 2026-11-02 |
| A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma Etentamig, Pomalidomide, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | AbbVie | 520 | 2026-11-30 | 2026-07-27 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Recruiting | Hoffmann-La Roche | 45 | 2026-11-03 | 2026-11-05 |
| Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. Belantamab Mafodotin, Pomalidomide, Dexamethasone - Relapsed / Refractory Multiple Myeloma | Phase 2 | Not yet recruiting | Polish Myeloma Consortium | 228 | 2026-10-01 | 2026-08-06 |
| Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma. Teclistamab (Tec) and Pomalidomide (Pom) - Multiple Myeloma Progression | Phase 2 | Not yet recruiting | Odense University Hospital | 50 | 2026-09-01 | 2026-08-11 |
| Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response Pomalidomide, Rituximab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 4 | Not yet recruiting | The First Hospital of Jilin University | 27 | 2026-09-01 | 2026-08-12 |
| TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) Talquetamab, Belantamab mafodotin, Pomalidomide - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Montefiore Medical Center | 50 | 2026-09-01 | 2026-07-22 |
| Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma Biospecimen Collection, Pomalidomide - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | University of Michigan Rogel Cancer Center | 12 | 2026-08-26 | 2026-10-15 |
| Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma InoPd, Investigator's choice of SAT - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 3 | Recruiting | CellCentric Ltd. | 450 | 2026-08-01 | 2026-08-19 |
| Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab - DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma) | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 53 | 2026-07-25 | 2026-08-06 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Recruiting | Hoffmann-La Roche | 380 | 2026-06-23 | 2026-10-13 |
| A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA) BCD-248 + daratumumab, Daratumumab + pomalidomide + dexamethasone - Myeloma Multiple | Phase 3 | Recruiting | Biocad | 390 | 2026-06-15 | 2026-08-03 |
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection) - Relapsed or Refractory Multiple Myeloma | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 255 | 2026-06-11 | 2026-09-17 |
| Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma TQB2934 injection, Pomalidomide Capsule, Selinexor tablets - Multiple Myeloma | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 260 | 2026-06-01 | 2026-05-08 |
| QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms QLS4131, QL2109, Pomalidomide - Malignant Plasma Cell Neoplasms | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 162 | 2026-06-01 | 2026-05-01 |
| Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma Belantamab mafodotin, Bortezomib, Dexamethasone - Relapse Multiple Myeloma | Not yet recruiting | PETHEMA Foundation | 100 | 2026-06-01 | 2026-06-24 | |
| Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma Pomalidomide - Indolent Lymphoma, Follicular Lymphoma | Not yet recruiting | The First Affiliated Hospital of Soochow University | 30 | 2026-05-01 | 2026-05-27 |
Showing 20 of 298. Sign in to see all of them.
Multiple Myeloma (212) · Recurrence (54) · Neoplasms, Plasma Cell (20) · Neoplasms (15) · Immunoglobulin Light-chain Amyloidosis (11) · Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma, Non-Hodgkin (5) · Amyloidosis (4) · Hematologic Diseases (4) · Lymphoma, B-Cell (4) · Myeloproliferative Disorders (4) · Blood Protein Disorders (3) · Burkitt Lymphoma (3) · Hematologic Neoplasms (3) · Leukemia, Myeloid, Acute (3)
Celgene (35) · National Cancer Institute (NCI) (12) · Janssen Research & Development, LLC (11) · Mayo Clinic (11) · AbbVie (9) · GlaxoSmithKline (8) · Sanofi (7) · Bristol-Myers Squibb (6) · Massachusetts General Hospital (5) · Oncotherapeutics (5) · Qilu Pharmaceutical Co., Ltd. (5) · Weill Medical College of Cornell University (5) · Amgen (4) · M.D. Anderson Cancer Center (4) · Canadian Myeloma Research Group (3)
United States (194) · Spain (69) · France (64) · Germany (60) · Italy (57) · China (55) · Canada (54) · United Kingdom (54) · Australia (48) · Japan (44) · Greece (42) · Belgium (35) · Netherlands (33) · Poland (32) · South Korea (32)
James R Berenson, MD (5) · Edward O'Mara, MD (3) · Evangelos Terpos, Prof (3) · Lars Sternas, MD, PhD (3) · Ramya M Ramaswami, M.D. (3)
PMID 27267105, PMID 35876974, PMID 40226119, PMID 41627370, PMID 10564685, PMID 15902208, PMID 15958804, PMID 17975015, PMID 18032762, PMID 18032763, PMID 19901123, PMID 21690557, PMID 22081489, PMID 22493299, PMID 23243282, PMID 23319574, PMID 23370364, PMID 23417027, PMID 23890523, PMID 23954889, PMID 24007748, PMID 24421329, PMID 25047979, PMID 25425684, PMID 25439689, PMID 25482239, PMID 25575538, PMID 25629741, PMID 25869284, PMID 26149712, PMID 26160879, PMID 26248505, PMID 26250580, PMID 26384354, PMID 26913560, PMID 26932802, PMID 26943915, PMID 27081177, PMID 27096106, PMID 27102499, PMID 27173785, PMID 27269947, PMID 27381904, PMID 27773929, PMID 27774990, PMID 27863194, PMID 27879257, PMID 28130212, PMID 28193568, PMID 28461396
2023 (22), P30CA015083 (6), 2018 (5), 2019 (5), 2016 (4), 2025 (4), 2014 (3), 2009 (2), 2015 (2), 2017 (2), P30CA138292 (2), U10CA180820 (2), UM1CA121947 (2), P30CA006973 (1), P30CA043703 (1)